Recently, Xinda Bio released news that the early RMB fund it initiated and led, Suzhou Xinhe Guoqing Fund, successfully completed the fundraising and closed all accounts.
The fund size is 500 million yuan, and the fund manager is Suzhou Xincheng Private Equity Fund Management Co.
,
Ltd.
It is reported that Suzhou Xinhe Guoqing Fund is a venture capital fund jointly established by Cinda Bio and Yuanhe Holdings as general partners and led by Cinda Bio
.
The fund focuses on early-stage investments in leading companies in innovative medicine, biotechnology and industry chain-related fields, focusing on empowering next-generation biomedicine and breakthrough technologies to address unmet clinical needs
.
In fact, in recent years, not only Cinda, but also pharmaceutical companies have entered the field of private equity, and more and more cases have turned into private equity fund LPs
.
For example, within one month of March last year, Tigermed announced that it had invested in 5 funds, involving Boyuan Capital, Hankang Capital, Lingang Life Blue Bay Fund, Yunfeng Fund, and a joint venture fund initiated by Ruihua Holdings.
The new fund has a total investment of 520 million yuan
.
This year, according to incomplete statistics, as of August, more than 20 listed pharmaceutical companies have issued announcements to participate in or initiate the establishment of industrial investment funds
.
For example, in May, the biomedical professional fund with a total scale of about 10 billion yuan jointly established by Vivo Capital and Kexing Biotech completed the first round, with a scale of 4 billion
.
On June 2, Anxu Biology announced that the company intends to use its own funds to invest with Zhongchuan Financial Holdings and Guohan Investment to initiate the establishment of Hangzhou Zhongchuan Anxu Equity Investment Partnership (Limited Partnership).
Long-term enterprises/projects in the fields of medicine, general health, and biomedicine
.
The total investment of the fund to be established this time shall not exceed 1 billion yuan
.
Among them, the company's subscription contribution does not exceed 500 million yuan, accounting for 50% of the total fund contribution
.
The initial investment amount is 200 million yuan, accounting for 40% of the total subscribed capital contribution
.
On June 6, Hengrui Pharmaceutical announced that the company intends to jointly establish the "Shanghai Shengdi Biomedical Fund" with its holding subsidiary Shengdi Investment and its controlling shareholder Hengrui Pharmaceutical Group.
The total subscribed capital contribution of the partnership is 2.
01 billion.
Yuan, of which Hengrui Medicine and Hengrui Group, as limited partners (LP), invested 1.
000 billion yuan respectively, with a shareholding ratio of 49.
75%
.
The source of funds of the company is its own funds
.
The announcement shows that the newly established investment fund will carry out equity investment business around the medical and health industry, invest in high-quality enterprises in the medical and health field, focus on innovative research and development in the field of biomedicine, and build a biomedical industry ecosystem and a leading domestic biomedical innovation investment platform.
.
On the whole, the purpose of pharmaceutical companies entering the field of private equity is basically to seek development outwards, but the methods are different.
Some choose to establish private equity funds, while others join in the form of capital investment
.
The industry believes that under the situation that the market continues to be under pressure, in addition to increasing investment in research and development, local pharmaceutical companies have also invested in private equity funds and have been regarded as the "second curve" for companies to seek growth
.
In the future, it is expected that a large number of pharmaceutical companies will use this to improve and enhance their competitiveness
.
